Your Health, We Care
Strong or moderate CYP3A4 inhibitors: Concomitant use increases encorafenib plasma concentrations, which may raise the risk of adverse reactions. Avoid concomitant use. If unavoidable, reduce the dose of encorafenib.
Strong CYP3A4 inducers: Concomitant use may decrease encorafenib plasma concentrations, which may reduce therapeutic efficacy. Avoid concomitant use.
Sensitive CYP3A4 substrates: Encorafenib is a strong CYP3A4 inducer at steady state. Concomitant use may decrease the plasma concentrations of CYP3A4 substrates (including hormonal contraceptives), which may reduce the efficacy of these substrates. Avoid concomitant use. If unavoidable, refer to the recommendations in the product labeling of the CYP3A4 substrate.
OATP1B1, OATP1B3, or BCRP substrates: Concomitant use may increase substrate concentrations, which may raise the risk of toxicity of these drugs. When used concomitantly, closely monitor patients for signs and symptoms of increased exposure, and consider adjusting the dose of these substrates.
Drugs that prolong the QT interval: Encorafenib is associated with dose-dependent QTc interval prolongation. Avoid concomitant use with drugs known to prolong the QT/QTc interval.
FDA，2025.03
